Immunogenetic analysis of B-cell malignancies and the clinical application of DNA idiotypic vaccines
Immunogenetic analysis of B-cell malignancies and the clinical application of DNA idiotypic vaccines
The first part of this thesis focuses on immunogenetic analysis of tumour idiotypes and their generation to gain further insight into the nature of the tumour antigen and the cell of origin. Follicular lymphoma (FL) and chronic lymphocytic leukaemia (CLL) were studied.
Most patients with FL have somatically mutated V genes, consistent with location in the germinal centre site. Remarkably, this study showed 79% of these lymphomas had potential N-glycosylation sites introduced into their V genes as a result of somatic hypermutation. One possibility is that added carbohydrate in the variable region may interact with elements in the germinal centre environment and be critical for tumour behaviour. The maturation stage of CLL is more controversial. It consists of two prognostic subsets, distinguished by the incidence of somatic mutations in the Ig V-genes. Activation induced cytidine deaminase (AID), a protein essential for somatic hypermutation, is expressed by germinal centre B-cells in which this process occurs. Surprisingly, analysis of AID mRNA in CLL showed that cases with unmutated Ig V genes express high levels. In addition, transcripts of AID splice variants were detectable. This raises the possibility that the unmutated subset arises from antigen-experienced B-cells rather than naïve B-cells.
The second part of this thesis focuses on the clinical application of DNA idiotypic vaccines in the treatment of B-cell malignancies. As with any vaccine, the clinical setting is critical and requires adequate immune capacity. The integrity of the immune system in patients with B-cell malignancies was therefore assessed by measuring their antibody response to vaccination with a conventional protein vaccine, tetanus toxoid. Response rates, as measured by a two fold increase in baseline values were 57% (8/14) in CLL stage A, 71% (11/14) in the diffuse large cell lymphoma and 72% (8/11) FL patients.
University of Southampton
McCarthy, Helen
26fef320-0597-4a97-b054-f2ae8e8a50d7
2004
McCarthy, Helen
26fef320-0597-4a97-b054-f2ae8e8a50d7
McCarthy, Helen
(2004)
Immunogenetic analysis of B-cell malignancies and the clinical application of DNA idiotypic vaccines.
University of Southampton, Doctoral Thesis.
Record type:
Thesis
(Doctoral)
Abstract
The first part of this thesis focuses on immunogenetic analysis of tumour idiotypes and their generation to gain further insight into the nature of the tumour antigen and the cell of origin. Follicular lymphoma (FL) and chronic lymphocytic leukaemia (CLL) were studied.
Most patients with FL have somatically mutated V genes, consistent with location in the germinal centre site. Remarkably, this study showed 79% of these lymphomas had potential N-glycosylation sites introduced into their V genes as a result of somatic hypermutation. One possibility is that added carbohydrate in the variable region may interact with elements in the germinal centre environment and be critical for tumour behaviour. The maturation stage of CLL is more controversial. It consists of two prognostic subsets, distinguished by the incidence of somatic mutations in the Ig V-genes. Activation induced cytidine deaminase (AID), a protein essential for somatic hypermutation, is expressed by germinal centre B-cells in which this process occurs. Surprisingly, analysis of AID mRNA in CLL showed that cases with unmutated Ig V genes express high levels. In addition, transcripts of AID splice variants were detectable. This raises the possibility that the unmutated subset arises from antigen-experienced B-cells rather than naïve B-cells.
The second part of this thesis focuses on the clinical application of DNA idiotypic vaccines in the treatment of B-cell malignancies. As with any vaccine, the clinical setting is critical and requires adequate immune capacity. The integrity of the immune system in patients with B-cell malignancies was therefore assessed by measuring their antibody response to vaccination with a conventional protein vaccine, tetanus toxoid. Response rates, as measured by a two fold increase in baseline values were 57% (8/14) in CLL stage A, 71% (11/14) in the diffuse large cell lymphoma and 72% (8/11) FL patients.
Text
981511.pdf
- Version of Record
More information
Published date: 2004
Identifiers
Local EPrints ID: 465605
URI: http://eprints.soton.ac.uk/id/eprint/465605
PURE UUID: a90bde83-aa40-4975-aebc-68d3670d9343
Catalogue record
Date deposited: 05 Jul 2022 02:00
Last modified: 16 Mar 2024 20:16
Export record
Contributors
Author:
Helen McCarthy
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics